Back to Results
First PageMeta Content
Organic chemistry / Organofluorides / Oncology / Triazoles / Aprepitant / Morpholines / Chemotherapy-induced nausea and vomiting / Cisplatin / 5-HT3 antagonist / Medicine / Chemistry / Antiemetics


XXXXXXX EMEND® (aprepitant) CAPSULES DESCRIPTION
Add to Reading List

Document Date: 2009-03-31 14:51:10

Open Document

File Size: 189,24 KB

Share Result on Facebook

Company

MERCK & CO. Inc. / Patients Who Remain Emesis Free / Cycle / Treatment Group / /

Event

FDA Phase / /

Facility

Whitehouse Station / /

IndustryTerm

aprepitant / /

MarketIndex

Functional Living / /

MedicalCondition

Secondary Endpoint No Vomiting / chemotherapy-induced nausea / maximum nausea visual analogue scale / Hepatic Insufficiency EMEND / ESRD / Nausea / No Significant Nausea / severe renal insufficiency / vomiting / renal insufficiency / severe hepatic insufficiency / postoperative nausea / vomiting endpoint / mild hepatic insufficiency / renal disease / end stage renal disease / breast cancer / moderate hepatic insufficiency / hepatic insufficiency / significant nausea / Renal Insufficiency A / /

MedicalTreatment

hemodialysis / chemotherapy / surgery / abdominal surgery / /

Organization

Oral administration / NS NS / Excretion Following administration / US Federal Reserve / Following administration / /

Product

EMEND / cisplatin / etoposide / dexamethasone / paclitaxel / cyclophosphamide / fluorouracil / ondansetron / EMEND® (aprepitant) / aprepitant / vomiting / /

ProvinceOrState

New Jersey / /

Technology

Pharmacokinetics / Tomography / chemotherapy / /

SocialTag